

Cyclopharm Ltd (CYC) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/C5D66DEF356EN.html>

Date: October 2021

Pages: 45

Price: US\$ 125.00 (Single User License)

ID: C5D66DEF356EN

Abstracts

Cyclopharm Ltd (CYC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cyclopharm Ltd (Cyclopharm) is a radiopharmaceutical company that manufactures medical and healthcare equipment and components in the nuclear medicine. The company's products include Technegas, an ultra-fine dispersion of technetium-labelled carbon used for detection of pulmonary embolism. The company is evaluating Technegas in new indications including chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary hypertension, lung volume reduction and Asthma. Cyclopharm operates a joint venture, Macquarie Medical Imaging, which provides diagnostic imaging services such as magnetic resonance imaging (MRI), computed tomography (CT), breast imaging, X-ray, ultrasound, dual-energy X-ray absorptiometry (DEXA) and positron emission tomography (PET) scanning. The company harnesses its Ultralute technology, which extends the life of Molybdenum-99 generators. It operates in Asia Pacific, Canada, Latin America, Europe and Germany. Cyclopharm is headquartered in New South Wales, Australia.

Cyclopharm Ltd Key Recent Developments

Aug 23,2021: Cyclopharm : Half year 2021 results – Revenues rebound

Feb 25,2021: Cyclopharm: Financial year 2020 results

Feb 05,2021: CYC receives 2020 R&D tax incentive - \$3.1 million

Jul 07,2020: Cyclopharm: 1H 2020 business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Cyclopharm Ltd - Key Facts
Cyclopharm Ltd - Key Employees
Cyclopharm Ltd - Key Employee Biographies
Cyclopharm Ltd - Major Products and Services
Cyclopharm Ltd - History
Cyclopharm Ltd - Company Statement
Cyclopharm Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Cyclopharm Ltd - Business Description
Business Segment: Molecular Imaging
Overview
Performance
Business Segment: Technegas
Overview
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: Canada
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Other
Performance
R&D Overview
Cyclopharm Ltd - Corporate Strategy
Cyclopharm Ltd - SWOT Analysis
SWOT Analysis - Overview
Cyclopharm Ltd - Strengths
Cyclopharm Ltd - Weaknesses

Cyclopharm Ltd - Opportunities
Cyclopharm Ltd - Threats
Cyclopharm Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cyclopharm Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 23, 2021: Cyclopharm : Half year 2021 results – Revenues rebound
Feb 25, 2021: Cyclopharm: Financial year 2020 results
Feb 05, 2021: CYC recieves 2020 R&D tax incentive - \$3.1 million
Jul 07, 2020: Cyclopharm: 1H 2020 business update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Cyclopharm Ltd, Key Facts
Cyclopharm Ltd, Key Employees
Cyclopharm Ltd, Key Employee Biographies
Cyclopharm Ltd, Major Products and Services
Cyclopharm Ltd, History
Cyclopharm Ltd, Subsidiaries
Cyclopharm Ltd, Joint Venture
Cyclopharm Ltd, Key Competitors
Cyclopharm Ltd, Ratios based on current share price
Cyclopharm Ltd, Annual Ratios
Cyclopharm Ltd, Annual Ratios (Cont...1)
Cyclopharm Ltd, Annual Ratios (Cont...2)
Cyclopharm Ltd, Interim Ratios
Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cyclopharm Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Cyclopharm Ltd, Performance Chart (2016 - 2020)

Cyclopharm Ltd, Ratio Charts

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Cyclopharm Ltd (CYC) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/C5D66DEF356EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5D66DEF356EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970